Prices delayed by 15 minutes
Next earnings report: 29 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Insmed Incorporated trades on Nasdaq under the ticker INSM. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks INSM has traded between 90.39 $ and 212.75 $. As of 09 October 2026 the price stood 8.25 % of the way from the 52-week low to the high.
Over one year INSM shares fell 38.10 %; over six months they fell 37.04 %. Volatility over 90 days is 65.64 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 26.5, above the sector median of 3.9. Price to book is 30.9, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 100.66 | 101.06 | 96.68 | 100.48 | 5M |
| 07 October 2026 | 103.87 | 104.80 | 101.60 | 101.74 | 3M |
| 06 October 2026 | 103.97 | 107.87 | 101.32 | 105.23 | 4M |
| 05 October 2026 | 105.50 | 108.75 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Insmed develops inhaled treatments for the lungs — the drug is delivered straight to the site.
The inhaled route creates a high concentration in the lungs with a modest burden on the body as a whole. The company's first approved drug treats a rare lung infection resistant to ordinary therapy and already brings revenue covering part of development costs.
The main bet is bronchiectasis, a chronic airway condition for which there was essentially no approved treatment. That market is an order of magnitude larger than the current one, and approval changes the company's scale. Such a stock moves on trial data and regulatory decisions rather than on results; development is funded by share issuance and debt. The company pays no dividend.
Address:700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807, US
Insmed Incorporated reported revenue of 820M $ and a net loss of 1.2B $ over the last four quarters. Net margin is −144.44 %. Revenue changed by +115.09 % year over year. Earnings per share are −5.76 $. Market capitalisation is 21.8B $.
INSM has a return on equity of −167.94 %, below the sector median of −41.68 %. Return on assets is −57.02 %, below the sector median of −32.11 %. Operating margin is −140.56 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 101.65 |
| 103.83 |
| 5M |
| 02 October 2026 | 107.76 | 111.54 | 105.68 | 111.12 | 4M |
| 01 October 2026 | 114.68 | 116.19 | 108.48 | 108.59 | 3M |
| 30 September 2026 | 115.65 | 116.43 | 113.60 | 114.14 | 3M |
| 29 September 2026 | 117.06 | 118.50 | 114.49 | 115.63 | 2M |
| 28 September 2026 | 116.83 | 119.32 | 116.31 | 117.67 | 2M |
| 25 September 2026 | 121.87 | 122.90 | 115.87 | 117.83 | 3M |
| 24 September 2026 | 119.26 | 121.69 | 118.38 | 121.55 | 2M |
| 23 September 2026 | 121.58 | 122.65 | 116.74 | 118.34 | 2M |
| 22 September 2026 | 121.00 | 122.48 | 119.09 | 120.82 | 2M |
| 21 September 2026 | 123.06 | 124.48 | 120.92 | 121.00 | 2M |
| 18 September 2026 | 123.89 | 124.11 | 119.32 | 120.00 | 3M |
| 17 September 2026 | 124.16 | 127.40 | 122.88 | 123.98 | 2M |
| 16 September 2026 | 120.00 | 124.41 | 119.55 | 122.58 | 1M |
| 15 September 2026 | 126.10 | 126.10 | 118.34 | 119.92 | 3M |
| 14 September 2026 | 129.50 | 130.78 | 124.58 | 125.30 | 2M |
| 11 September 2026 | 127.98 | 130.25 | 126.52 | 129.41 | 2M |